CORONA Remedies Limited has informed the Exchange about Transcript
CORONA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.2 pts more than Nifty Microcap 250 and 2.8 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
CORONA Remedies, recently listed on December 15, 2025, shared results from its maiden earnings call. Q2 FY26 revenue grew 15.1% YoY to INR 361.1 crores, with EBITDA up 17.4% to INR 78.5 crores (margin improved 40bps to 21.7%) and PAT up 21.8% to INR 52.3 crores. H1 FY26 revenue rose 17% to INR 707.7 crores, EBITDA grew 27.4% with margins up 170bps to 20.9%, and PAT jumped 35.1% to INR 98.5 crores. The company posted strong return ratios with annualized ROE of 31.1% and ROCE of 49.7%, and is net cash surplus. Management guided for 15% revenue CAGR and 20% PAT/EPS growth over the next 3-4 years, with plans to enter new therapeutic areas (infertility, nephrology, CNS, oncology, dermatology) and scale international business from 3.5% to 8-9% of revenue.
Strong debut results with margin expansion, robust return ratios, and clear multi-year growth guidance are positive signals. The 20% PAT growth target and net cash position support investor confidence, though execution of new therapy entries and the upcoming hormonal plant (commercial start targeted Q2/Q3 FY27) will be key watchpoints.